NHS Palantir platform's business case under pressure as costs rise and benefits fall
Company insists FDP remains on track
The business case for the NHS's flagship Federated Data Platform (FDP) is facing renewed scrutiny after official figures showed projected costs rising while expected benefits have been revised down, reigniting a controversy that has dogged Palantir's role in the health service since before the contract was awarded.
As reported by the Financial Times, the National Infrastructure and Service Transformation Authority's (NISTA) has revised the whole-life cost of the FDP programme upwards to £1.1 billion, while forecast benefits have fallen to £808 million. The government agency says the revised reflect a better understanding of the FDP’s performance, usage and adoption as it is rolled out.
The revisions come as government ministers decide whether to act on a break clause in the Palantir contract 2027, which would allow them to terminate the contract.
Questions over value for money
The FDP is intended to connect disparate NHS data systems, allowing organisations to share information more easily, with less duplication and waste.
Palantir points to the programme's continued green rating from NISTA, indicating that it remains on track from a project-delivery perspective. NHS England, meanwhile, claims that as the FDP is rolled out wider benefits will be realised.
However, researchers, doctors’ groups, health and privacy campaigners, government bodies and parliamentary committees have all challenged NHS England's claims about the platform's effectiveness.
Claims under scrutiny
In July, the Office for Statistics Regulation (OSR) instructed NHS England to strengthen caveats around claims made about FDP benefits after concerns that some conflated corelation with causation.
Meanwhile, Freedom of Information (FoI) requests by legal campaign group Foxglove found that nearly a third of NHS trusts that adopted the FDP's Inpatient Care Coordination Solution performed fewer operations than previously. The Health Foundation found "no noticeable improvement" in delayed discharge performance among trusts using OPTICA, a discharge-management tool built on FDP technology; the finding is disputed by Palantir.
A lack of transparency
Concerns about the FDP date back to the procurement process itself. Before the contract was awarded, NHS data specialists described Palantir's Foundry platform as expensive, proprietary and less capable than some existing NHS analytical tools, including open-source platforms less prone to vendor lock-in.
Concern was also expressed about Palantir's links to US intelligence, co-founder Peter Thiel's political activities and the company’s strategy of intensive lobbying to obtain its goals.
NHS England also faced criticism over a lack of transparency, publishing a heavily redacted version of the FDP contractwith entire sections relating to personal data protection and service recipients blanked out. Transparency concerns have persisted as parliamentary committees sought information about the platform's performance and business case.
Both the Science, Innovation and Technology Committee and the Health and Social Care Committee have urged ministers to consider using the 2027 break clause, and more than 100 NHS data and technology specialists have also called for the contract to be terminated.
The debate widened further this year when reports emerged that external contractors working on the FDP could access identifiable patient information. In August, NHS England apologised after admitting that a previous Data Protection Impact Assessment had inaccurately suggested that only NHS staff could access identifiable data, undermining a key data privacy claim.
Ministers are expected to decide in the coming months whether to continue the FDP contract beyond 2027. Weighed against concerns over its efficacy, value for money and data privacy and security, will be the cost of replacing it with an alternative data integration and analytics solution.